Truist Securities Maintains Buy on Perspective Therapeutics, Lowers Price Target to $8
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Gregory Renza maintains Perspective Therapeutics (AMEX:CATX) with a Buy and lowers the price target from $11 to $8.
Truist Securities analyst Gregory Renza maintains Perspective Therapeutics (AMEX:CATX) with a Buy and lowers the price target from $11 to $8.